Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 6/20 | 0.52 |
| ▸ | ESR1 | P03372 | 6/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7458538 | 0.97 | LTA4H (0.53) | LTA4HESR1ESR2MCHR1KCNH2 | |
| SCHEMBL7926791 | 0.90 | ESR1 (0.58) | LTA4HESR1ESR2 | |
| SCHEMBL7930071 | 0.87 | ESR1 (0.52) | LTA4HESR1ESR2MCHR1KCNH2 | |
| SCHEMBL30619817 | 0.86 | MAOB (0.44) | HTTRAB9ASMN1; SMN2 | |
| SCHEMBL7930070 | 0.85 | ESR1 (0.51) | LTA4HESR1ESR2 | |
| SCHEMBL4514205 | 0.84 | LTA4H (0.57) | LTA4HESR1ESR2MCHR1KCNH2 | |
| SCHEMBL10001885 | 0.81 | ESR1 (0.51) | ESR1ESR2 | |
| SCHEMBL30619840 | 0.80 | MAOB (0.41) | HTT | |
| SCHEMBL7178420 | 0.80 | ESR1 (0.76) | LTA4HESR1ESR2 | |
| SCHEMBL7749392 | 0.78 | LTA4H (0.61) | LTA4HESR1MCHR1KCNH2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1757291-A2 | Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof | Eli Lilly & Company (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1357903-B1 | STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4- 2-(PIPERIDIN-1-YL) ETHOXY|PHENOXY)-2-(4-METHOXYPHENYL) BENZO b|THIOPHENE AND SALTS THEREOF | LILLY CO ELI (US) | 2006-12-20 | — | — | EP | disclosed |
| US-7122203-B2 | Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof | ELI LILLY AND COMPANY (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1204655-B1 | A CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY] PHENOXY)-2-(4-METHOXYPHENYL)BENZO[B]THIOPHENE HYDROCHLORIDE | LILLY CO ELI (US) | 2003-10-01 | — | — | EP | disclosed |
| US-6610706-B1 | Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride | ELI LILLY AND COMPANY | 2003-08-26 | — | — | US | disclosed |
| US-20030119875-A1 | Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof | ELI LILLY AND COMPANY | 2003-06-26 | — | — | US | disclosed |
| US-20020013342-A1 | Treatment of central nervous system disorders with selective estrogen receptor modulators | BALES KELLY RENEE (US) | 2002-01-31 | — | — | US | disclosed |
| EP-0729956-B1 | Benzothiophene compounds, intermediates, compositions, and methods | LILLY CO ELI (US) | 2001-10-31 | — | — | EP | disclosed |
| EP-1113013-A1 | Benzothiophene compounds, intermediates, compositions and methods | Eli Lilly & Company (US) | 2001-07-04 | — | — | EP | disclosed |
| US-6197790-B1 | OSTEOPOROSIS | ELI LILLY AND COMPANY | 2001-03-06 | — | — | US | disclosed |
| US-6077852-A | ADMINISTERING TO THE PATIENT SUFFERING FROM ALZHEIMER'S DISEASE A SUBSTITUTED BENZOTHIOPHENE DERIVATIVE | ELI LILLY AND COMPANY (US) | 2000-06-20 | — | — | US | disclosed |
| US-6030986-A | POST-MENOPAUSAL SYNDROME, UTERINE FIBROID DISEASE, ENDOMETRIOSIS, AND AORTAL SMOOTH MUSCLE CELL PROLIFERATION; ESTROGEN INDUCED UTERINE CANCER; OSTEOPOROSIS; RESTENOSIS; CARDIOVASCULAR DISORDERS | ELI LILLY AND COMPANY (US) | 2000-02-29 | — | — | US | disclosed |
| US-5998441-A | ANTICHOLESTEROL AGENT; MIXTURE WITH ESTROGEN | ELI LILLY AND COMPANY (US) | 1999-12-07 | — | — | US | disclosed |
| US-5985898-A | INHIBITING HYPERLIPIDEMIA RESULTED FROM ESTROGEN DEFICIENCY DISEASE, REDUCING SERUM CHOLESTEROL, | ELI LILLY AND COMPANY (US) | 1999-11-16 | — | — | US | disclosed |
| US-5986109-A | UROGENITAL DISORDERS, CARDIOVASCULAR DISORDERS AND ANTICARCINOGENIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-11-16 | — | — | US | disclosed |
| US-5981765-A | FOR TREATMENT OF POST-MENOPAUSAL SYNDROME INCLUDING OSTEOPOROSIS, CARDIOVASCULAR EFFECTS SUCH AS HYPERLIPIDEMIA, AND ESTROGEN-DEPENDENT CANCER, PARTICULARLY BREAST AND UTERINE CANCER | ELI LILLY AND COMPANY (US) | 1999-11-09 | — | — | US | disclosed |
| US-5977093-A | INHIBITING ESTROGEN-DEPENDENT CANCER | ELI LILLY AND COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
| US-5969142-A | OXIDIZING SULFUR ATOM OF SUBSTITUTED BENZOTHIOPHENE, REACTING PRODUCT WITH NUCLEOPHILIC GROUP, REDUCING PRODUCT TO DESIRED COMPOUND | ELI LILLY AND COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0729956-A1 | Benzothiophene compounds, intermediates, compositions, and methods | ELI LILLY AND COMPANY (US) | 1996-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119875-A1 | Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof | TPMT, BHMT2, TST | LTA4H 268/4885ESR1 4324/4885ESR2 3666/4885 |
| US-20020013342-A1 | Treatment of central nervous system disorders with selective estrogen receptor modulators | ESR1, ESRRA, ESR2 | LTA4H 3567/4885ESR1 1/4885ESR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.